Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Pasi Antero Janne, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Pasi Janne and Bruce Johnson.
Connection Strength

3.509
  1. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20.
    View in: PubMed
    Score: 0.348
  2. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4416s-4420s.
    View in: PubMed
    Score: 0.344
  3. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):751-8.
    View in: PubMed
    Score: 0.333
  4. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005 May 10; 23(14):3227-34.
    View in: PubMed
    Score: 0.317
  5. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004 May; 44(2):213-20.
    View in: PubMed
    Score: 0.295
  6. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004 May; 44(2):221-30.
    View in: PubMed
    Score: 0.295
  7. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7.
    View in: PubMed
    Score: 0.264
  8. Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy. J Surg Oncol. 2018 Dec; 118(7):1170-1177.
    View in: PubMed
    Score: 0.200
  9. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16; 448(7155):807-10.
    View in: PubMed
    Score: 0.093
  10. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15; 67(10):4933-9.
    View in: PubMed
    Score: 0.091
  11. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43.
    View in: PubMed
    Score: 0.091
  12. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6.
    View in: PubMed
    Score: 0.089
  13. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706.
    View in: PubMed
    Score: 0.086
  14. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.
    View in: PubMed
    Score: 0.086
  15. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95.
    View in: PubMed
    Score: 0.085
  16. Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 2005 Nov 15; 11(22):8122-30.
    View in: PubMed
    Score: 0.082
  17. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology. 2005; 68(4-6):500-10.
    View in: PubMed
    Score: 0.080
  18. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004 Oct 15; 64(20):7241-4.
    View in: PubMed
    Score: 0.076
  19. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 2004 Apr 08; 23(15):2716-26.
    View in: PubMed
    Score: 0.073
  20. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501.
    View in: PubMed
    Score: 0.042
  21. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89.
    View in: PubMed
    Score: 0.030
  22. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23.
    View in: PubMed
    Score: 0.027
  23. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
    View in: PubMed
    Score: 0.022
  24. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 01; 23(25):5900-9.
    View in: PubMed
    Score: 0.020
  25. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3788-93.
    View in: PubMed
    Score: 0.020
  26. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.